Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program

BACKGROUND: Selinexor (KPT-330) is an inhibitor of the major nuclear export receptor, exportin 1 (XPO1, also termed chromosome region maintenance 1, CRM1) that has demonstrated activity in preclinical models and clinical activity against several solid and hematological cancers. PROCEDURES: Selinexor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Attiyeh, Edward F., Maris, John M., Lock, Richard, Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Landesman, Yosef, Shacham, Sharon, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722540/
https://ncbi.nlm.nih.gov/pubmed/26398108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados